Contribute Try STAT+ Today

Rise and shine, everyone, another demanding day is on the way. We can tell if only because our official mascot bounded out of the castle for his morning constitutional, a signal that routines must be followed. Speaking of which, we are brewing a few cups of stimulation to power our own routine. Our flavor today is — brace yourself — glazed doughnut. Meanwhile, here are a few items of interest to help you on your own journey. We hope your day is productive and safe. And as always, do keep in touch. We accept saucy tidbits and secret dossiers. …

Russian President Vladimir Putin says his country registered the world’s first Covid-19 vaccine, marking a milestone in the fight against the novel coronavirus but coming amid rising safety concerns in the West over the country’s accelerated clinical evaluations, The Wall Street Journal writes. Scientists at the Gamaleya Institute in Moscow employed military testing, accelerated clinical evaluations, and shortened test-trial times in an attempt to be first with a vaccine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.